Search criteria | ||||
Exploring current practice, knowledge, and challenges of sexually transmitted infection/HIV management and pre-exposure prophylaxis among Japanese health care professionals: a cross-sectional web survey | ||||
Mayuko Kamakura 1, Daisuke Fukuda 1, Naho Kuroishi 1, Dilinuer Ainiwaer 2, Junko Hattori 1 (rwesheorj 2) | ||||
1) Medical Affairs, MSD K.K., Tokyo, Japan 2) IQVIA Solutions Japan K.K., Tokyo, Japan | ||||
AIDS Patient Care and STDs |
||||
, Article | ||||
, Japan | ||||
Abstract: https://www.liebertpub.com/doi/10.1089/apc.2023.0013 | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2023 | English | , Survey research | |
English demographics and cost of HIV-associated comorbidities in individuals over the age of 35: an investigation using the Hospital Episode Statistics (HES) database | ||||
Wild L, Smith A, Sathia L, Davies S, Fernandez DP, Lawrence D. | ||||
1Gilead Sciences, London, UK, 2IQVIA, London, UK | ||||
HIV MEDICINE 2018 Apr 1 (Vol. 19, pp. S76-S77). |
||||
, Abstract, Poster | ||||
, England | ||||
Abstract: https://onlinelibrary.wiley.com/doi/10.1111/hiv.12614 | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2022 | English | , Cost consequence, Cost of illness, Database Study, Population Based Study | |
Potential Healthcare Resource Use And Associated Costs Of Every 2 months Injectable Cabotegravir+Rilpivirine Long-acting Implementation In The Spanish NHS Vs. Daily Oral HIV Treatments | ||||
Laura-Amanda Vallejo Aparicio (1), Victoria Neches GarcÃa (1), Beatriz Hernández (2), Gregorio Casado (3), Ferrán Jodar (3), Marco Pinel (3), Daniel Callejo Velasco (3) | ||||
(1) GSK, Tres Cantos (Madrid), España; (2) ViiV Healthcare, Tres Cantos (Madrid), España; (3)IQIVA, España | ||||
ISPOR Europe 2022; November 6-9, 2022; Virtual and Vienna, Austria |
||||
, Poster | ||||
, Spain | ||||
Abstract: https://www.ispor.org/docs/default-source/euro2022/ee379cabotegravirrilpivirinelahruassociatedcosts-pdf.pdf?sfvrsn=4efb8fca_0 | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS, Infectious disease | 2022 | English | , Burden of illness, Cost analysis, Public Health | |
Potential Healthcare Resource Use And Associated Costs Of Every 2 months Injectable Cabotegravir+Rilpivirine Long-acting Implementation In The Spanish NHS Vs. Daily Oral HIV Treatments | ||||
Laura-Amanda Vallejo Aparicio1 , Victoria Neches GarcÃa1 , Beatriz Hernández 2 , Gregorio Casado3 , Ferrán Jodar 3 , Marco Pinel 3 , Daniel Callejo Velasco3 | ||||
1GSK, Tres Cantos (Madrid), España; 2ViiV Healthcare, Tres Cantos (Madrid), España; 3IQIVA, España | ||||
ISPOR Europe 2022; November 6-9, 2022; Virtual and Vienna, Austria |
||||
, Poster | ||||
, Spain | ||||
Abstract: https://www.ispor.org/docs/default-source/euro2022/ee379cabotegravirrilpivirinelahruassociatedcosts-pdf.pdf?sfvrsn=4efb8fca_0 | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS, Infectious disease | 2022 | English | ||
THE COST OF STIGMA ASSOCIATED WITH HIV- A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA | ||||
Filemban S1, Elrashied S1, Assiri A1, Hakawi A1, Snehanshu S2, Mansour E3, Vemer P4, Awad N5 | ||||
1Ministry of Health, Riyadh, Saudi Arabia, 2Gilead Sciences Middle East, Dubai Health Care City, United Arab Emirates, 3Gilead, Dubai, United Arab Emirates, 4Groningen University, Groningen, Netherlands, 5IQVIA, Dubai, United Arab Emirates | ||||
2019-11, ISPOR Europe 2019, Copenhagen, Denmark |
||||
, Poster | ||||
, Saudi Arabia | ||||
Abstract: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3120/97847 | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2019 | English | , Predictive analytics, Quality of life | |
Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States. | ||||
Dekoven M, Makin C, Slaff S, Marcus M, Maiese EM. | ||||
IMS Health, Fairfax, VA, USA. Yoh Services LLC, Philadelphia, PA, USA. Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA emaiese@gmail.com | ||||
J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):66-76 |
||||
, Article | ||||
, USA | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/26224690 | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2016 | English | , Retrospective database analysis | |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. | ||||
Moeremans K1, Hemmett L2, Hjelmgren J3, Allegri G4, Smets E5 | ||||
1 IMS Health, Brussels, Belgium 2 Tibotec, Buckinghamshire, UK 3 Janssen-Cilag AB, Stockholm, Sweden 4 Janssen-Cilag SpA, Cologno Monzese, Italy 5 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium | ||||
Pharmacoeconomics, 2010, 28 (Suppl 1): 147-167 |
||||
, Article | ||||
, Belgium, Italy, Nordic, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2010 | English | , Cost effectiveness | |
Cost-effectiveness of etravirine in Sweden in treatment-experienced HIV-1-infected adults with evidence of NNRTI resistance and ? 3 PI mutations. | ||||
Moeremans K1, Hjelmgren J2, Martin S3 | ||||
1 IMS Health, Brussels, Belgium 2 Janssen-Cilag, Birkeöd, Denmark 3 J&J, Mechelen, Belgium | ||||
12th European Aids Conference, 2009, November 11-14, Cologne, Germany ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2009 | English | , Cost utility | |
Cost effectiveness of darunavir/ritonavir 600/100mg BID in treatment-experienced, LPV/R-naïve, PI-resistent, HIV-infected adults in the United Kingdom, Belgium, Italy and Sweden. | ||||
Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E | ||||
ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
, Oral presentation | ||||
, Belgium, Italy, Sweden, UK | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2008 | English | , Cost effectiveness | |
Cost-Effectiveness Analysis of Enfuvirtide (ENF) Added to an Optimized Therapy vs an Optimized Therapy Alone in Patients With HIV/AIDS. | ||||
Badia X, Lizan L, Magaz S, Alvarez C, Green J, Serrano D. | ||||
HIV Clinical Trials 2007;8(4):235-45 |
||||
, Manuscript in preparation | ||||
, Spain | ||||
Abstract: http://www.druglib.com/abstract/ba/badia-x_hiv-clin-trials_20070700.html | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2007 | English | , Cost effectiveness | |
Experienced HIV/AIDS patients in different European healthcare settings | ||||
Moeremans Karen, Annemans Lieven,; Smets Erik, Wyffels Veronique, Lothgren Mickael , Allegri Gabriele | ||||
ISPOR 2007 10th Annual European Congress |
||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2007 | English | ||
Cost of care for HIV/AIDS in Belgium according to disease stage. | ||||
Caekelbergh K1, Moeremans K1, Annemans L2, De Roo A3, Clumeck N4, Van Wijngaerden E5, Vandercam B6, Moutschen M7, Smets E8 | ||||
1 IMS Health, Brussels, Belgium 2 Ghent University, Ghent, Belgium 3 Institute for Tropical Medicine, Antwerp, Belgium 4 St. Pierre University Hospital, Brussels, Belgium 5 University Hospital Leuven, Belgium 6 University Hospital St. Luc, Brussels, Belgium 7 University Hospital Sart Tilman, Liège, Belgium 8 Johnson & Johnson Pharmaceutical Services, Mechelen, Belgium | ||||
11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain |
||||
, Oral presentation | ||||
, Belgium | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2007 | English | , Cost of illness | |
Cost-effectiveness of DRV/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings. | ||||
Moeremans K, Annemans L, Smets E, Wyffels V, Wilson B, Lothgren M, Allegri G | ||||
11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain |
||||
, Oral presentation | ||||
, Belgium | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2007 | English | , Cost effectiveness | |
Cost-effectiveness of Darunavir/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings. | ||||
Moeremans K, Annemans L, Smets E, Wyffels V, Lothgren M, Allegri G | ||||
ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland |
||||
, Oral presentation | ||||
, Belgium | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2007 | English | , Cost effectiveness | |
Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with HIV. | ||||
Munakata J, Benner JS, Becker SL, Dezii CM, Hazard EH, Tierce JC. | ||||
Medical Care 2006;44(10):893-899. |
||||
, Manuscript in preparation | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2006 | English | ||
Evaluation of a HCV Patient Support Program’s Impact on Patient Adherence. | ||||
M. Hussein, J. S. Benner, D. Lee, and others. Evaluation of a HCV Patient Support Program’s Impact on Patient Adherence. (Oral Presentation). Digestive Disease Week 2006 (DDW 2006). May 20-25, 2006. Los Angeles, CA. | ||||
Digestive Disease Week 2006 (DDW 2006). May 20-25, 2006. Los Angeles, CA. |
||||
, Oral presentation | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2006 | English | ||
Evaluation of a program to improve adherence with pegylated interferon therapy: a propensity score matched retrospective cohort analysis. | ||||
Mohamed Hussein, Joshua S. Benner, David Lee, Anne-Marie Sesti, David S. Battleman. | ||||
Internation Society for pharmacoeconomics and outcomes research (ISPOR 2007). May 20-24, 2006. Philadelphia, PA |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, HIV AIDS | 2006 | English | ||